AACR 2024 – Akeso impresses in stomach cancer
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
